These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 35126995)

  • 1. IgE and high-affinity IgE receptor in chronic inducible urticaria, pathogenic, and management relevance.
    Giménez-Arnau AM; Ribas-Llauradó C; Mohammad-Porras N; Deza G; Pujol RM; Gimeno R
    Clin Transl Allergy; 2022 Feb; 12(2):e12117. PubMed ID: 35126995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relevance of the Basophil High-Affinity IgE Receptor in Chronic Urticaria: Clinical Experience from a Tertiary Care Institution.
    Deza G; March-Rodríguez A; Sánchez S; Ribas-Llauradó C; Soto D; Pujol RM; Gimeno R; Giménez-Arnau AM
    J Allergy Clin Immunol Pract; 2019; 7(5):1619-1626.e1. PubMed ID: 30685572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IgE receptor responsiveness of basophils in chronic inducible urticaria.
    Mizuno M; Oda Y; Imamura S; Washio K; Fukumoto T; Fukunaga A
    Front Immunol; 2022; 13():995596. PubMed ID: 36211415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved FcεRI-Mediated CD203c Basophil Responsiveness Reflects Rapid Responses to Omalizumab in Chronic Spontaneous Urticaria.
    Oda Y; Fukunaga A; Washio K; Imamura S; Mizuno M; Hatakeyama M; Ogura K; Nishigori C
    J Allergy Clin Immunol Pract; 2021 Mar; 9(3):1166-1176.e8. PubMed ID: 32898709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response of FcεRI-bearing leucocytes to omalizumab in chronic spontaneous urticaria.
    Alizadeh Aghdam M; Knol EF; van den Elzen M; den Hartog Jager C; van Os-Medendorp H; Knulst AC; Otten HG; Röckmann H
    Clin Exp Allergy; 2020 Mar; 50(3):364-371. PubMed ID: 31925825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcεRI-positive cells in the skin.
    Metz M; Staubach P; Bauer A; Brehler R; Gericke J; Kangas M; Ashton-Chess J; Jarvis P; Georgiou P; Canvin J; Hillenbrand R; Erpenbeck VJ; Maurer M
    Theranostics; 2017; 7(5):1266-1276. PubMed ID: 28435464
    [No Abstract]   [Full Text] [Related]  

  • 7. Double-blind placebo-controlled trial of the effect of omalizumab on basophils in chronic urticaria patients.
    Jörg L; Pecaric-Petkovic T; Reichenbach S; Coslovsky M; Stalder O; Pichler W; Hausmann O
    Clin Exp Allergy; 2018 Feb; 48(2):196-204. PubMed ID: 29164723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between changes in the 7-day urticaria activity score after treatment with omalizumab and the responsiveness of basophils to FcεRI stimulation in patients with chronic spontaneous urticaria.
    Endo T; Toyoshima S; Hayama K; Tagui M; Niwa Y; Ito M; Terui T; Okayama Y
    Asia Pac Allergy; 2020 Apr; 10(2):e12. PubMed ID: 32411577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Omalizumab treatment and outcomes in Chinese patients with chronic spontaneous urticaria, chronic inducible urticaria, or both.
    Chen Y; Yu M; Huang X; Tu P; Shi P; Maurer M; Zhao Z
    World Allergy Organ J; 2021 Jan; 14(1):100501. PubMed ID: 33510832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy of omalizumab treatment in chronic spontaneous urticaria is associated with basophil phenotypes.
    Johal KJ; Chichester KL; Oliver ET; Devine KC; Bieneman AP; Schroeder JT; MacGlashan DW; Saini SS
    J Allergy Clin Immunol; 2021 Jun; 147(6):2271-2280.e8. PubMed ID: 33713769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Basophil FcεRI Expression in Chronic Spontaneous Urticaria: A Potential Immunological Predictor of Response to Omalizumab Therapy.
    Deza G; Bertolín-Colilla M; Pujol RM; Curto-Barredo L; Soto D; García M; Hernández P; Gimeno R; Giménez-Arnau AM
    Acta Derm Venereol; 2017 Jun; 97(6):698-704. PubMed ID: 28303277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response of peripheral blood basophils in subjects with chronic spontaneous urticaria during treatment with omalizumab.
    MacGlashan D; Saini S; Schroeder JT
    J Allergy Clin Immunol; 2021 Jun; 147(6):2295-2304.e12. PubMed ID: 33716077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Omalizumab may not inhibit mast cell and basophil activation in vitro.
    Gericke J; Ohanyan T; Church MK; Maurer M; Metz M
    J Eur Acad Dermatol Venereol; 2015 Sep; 29(9):1832-6. PubMed ID: 25257818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low Responsiveness of Basophils via FcεRI Reflects Disease Activity in Chronic Spontaneous Urticaria.
    Oda Y; Fukunaga A; Washio K; Imamura S; Hatakeyama M; Ogura K; Nishigori C
    J Allergy Clin Immunol Pract; 2019; 7(8):2835-2844.e7. PubMed ID: 31136822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Roles for the High Affinity IgE Receptor, FcεRI, of Human Basophils in the Pathogenesis and Therapy of Allergic Asthma: Disease Promotion, Protection or Both?
    Youssef LA; Schuyler M; Wilson BS; Oliver JM
    Open Allergy J; 2010; 3():91-101. PubMed ID: 25018787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Basophil FcepsilonRI histamine release parallels expression of Src-homology 2-containing inositol phosphatases in chronic idiopathic urticaria.
    Vonakis BM; Vasagar K; Gibbons SP; Gober L; Sterba PM; Chang H; Saini SS
    J Allergy Clin Immunol; 2007 Feb; 119(2):441-8. PubMed ID: 17125820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomarkers of Autologous Whole Blood Injection Efficacy in Patients with Chronic Spontaneous Urticaria with Autoreactivity: A Preliminary Study.
    Chen Q; Luo J; Yang X; Chen W; Liu W; Song Z
    Int Arch Allergy Immunol; 2024; 185(2):190-195. PubMed ID: 37952519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional and phenotypic analysis of basophils allows determining distinct subtypes in patients with chronic urticaria.
    Rauber MM; Pickert J; Holiangu L; Möbs C; Pfützner W
    Allergy; 2017 Dec; 72(12):1904-1911. PubMed ID: 28585360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activated steady status and distinctive FcεRI-mediated responsiveness in basophils of atopic dermatitis.
    Imamura S; Washio K; Mizuno M; Oda Y; Fukunaga A; Nishigori C
    Allergol Int; 2021 Jul; 70(3):327-334. PubMed ID: 33674191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Omalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophils.
    Lin H; Boesel KM; Griffith DT; Prussin C; Foster B; Romero FA; Townley R; Casale TB
    J Allergy Clin Immunol; 2004 Feb; 113(2):297-302. PubMed ID: 14767445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.